Early identification of stimulant treatment responders, partial responders and non-responders using objective measures in children and adolescents with hyperkinetic disorder.
暂无分享,去创建一个
[1] Martin H. Teicher,et al. Novel strategy for the analysis of CPT data provides new insight into the effects of methylphenidate on attentional states in children with ADHD. , 2004, Journal of child and adolescent psychopharmacology.
[2] J. Swanson,et al. Weekend holidays during methylphenidate use in ADHD children: a randomized clinical trial. , 2004, Journal of child and adolescent psychopharmacology.
[3] J. Swanson,et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). , 2004, Pediatrics.
[4] W. Pelham,et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. , 2001, Pediatrics.
[5] Martin H. Teicher,et al. Rate dependency revisited: understanding the effects of methylphenidate in children with attention deficit hyperactivity disorder. , 2003, Journal of child and adolescent psychopharmacology.
[6] M. Byrnes,et al. A clinical protocol for determining methylphenidate dosage levels in ADHD , 1997 .
[7] Martin H. Teicher,et al. Objective measurement of hyperactivity and attentional problems in ADHD. , 1996, Journal of the American Academy of Child and Adolescent Psychiatry.
[8] John Hattie,et al. A Review of the Research on Interventions for Attention Deficit Hyperactivity Disorder: What Works Best? , 2002 .
[9] J. Swanson,et al. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. , 2004, Pediatrics.
[10] Martin H. Teicher,et al. Utility of objective measures of activity and attention in the assessment of therapeutic response to stimulants in children with attention-deficit/hyperactivity disorder. , 2008, Journal of child and adolescent psychopharmacology.
[11] C. Conners,et al. Clinical use of rating scales in diagnosis and treatment of attention-deficit/hyperactivity disorder. , 1999, Pediatric clinics of North America.
[12] C. Reynolds,et al. Effects of stimulants on the continuous performance test (CPT): implications for CPT use and interpretation. , 2001, The Journal of neuropsychiatry and clinical neurosciences.
[13] H. DeCory,et al. Methylphenidate bioavailability from two extended-release formulations. , 2002, International journal of clinical pharmacology and therapeutics.
[14] D. Coury,et al. Evaluating Medication Response in ADHD , 1998, Journal of learning disabilities.
[15] R. Barkley. The ecological validity of laboratory and analogue assessment methods of ADHD symptoms , 1991, Journal of abnormal child psychology.
[16] H Meltzer,et al. Using the Strengths and Difficulties Questionnaire (SDQ) to screen for child psychiatric disorders in a community sample , 2003, International review of psychiatry.
[17] S. Dalsgaard,et al. Is OPTAx™ useful for monitoring the effect of stimulants on hyperactivity and inattention? , 2007, European Child & Adolescent Psychiatry.
[18] M. Kosorok,et al. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. , 2001, Pediatrics.
[19] B. Herpertz-Dahlmann,et al. Differential effects of methylphenidate on attentional functions in children with attention-deficit/hyperactivity disorder. , 2004, Journal of the American Academy of Child and Adolescent Psychiatry.
[20] J. Hebebrand,et al. Objective measurement of hyperactivity, impulsivity, and inattention in children with hyperkinetic disorders before and after treatment with methylphenidate , 2004, European Child & Adolescent Psychiatry.